{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK7",
        "Protein_Change": {
          "ref": "M",
          "alt": "I",
          "position": "26"
        },
        "variant_string_id": "PARK7 M26I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD)-associated genomic deletions and the destabilizing L166P point mutation lead to loss of the cytoprotective DJ-1 protein.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as loss of DJ-1 protein function in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We measured suppression of apoptosis signal-regulating kinase 1 (ASK1) and cytotoxicity for [M26I]DJ-1, and systematically all other DJ-1 methionine and cysteine mutants.",
          "judgment": "Yes",
          "reasoning": "Protein interaction assays (ASK1 binding) and cytoprotection assays are directly relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Systematic testing of all DJ-1 methionine and cysteine mutants, including wild-type (wt) and [M26I]DJ-1 in null backgrounds.",
          "judgment": "Yes",
          "reasoning": "Wild-type and known pathogenic variants (e.g., L166P) were used as controls. Systematic testing implies replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants (e.g., L166P) and benign variants (peripheral cysteine mutants) were compared to [M26I]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Variant controls (pathogenic and benign) were explicitly used for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study systematically tested all cysteine and methionine mutants, with [M26I]DJ-1 causing complete loss of protein in null backgrounds.",
          "judgment": "No",
          "reasoning": "The abstract does not specify statistical analyses (e.g., p-values, effect sizes) for [M26I]DJ-1.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested all cysteine and methionine mutants but does not specify the total number of control variants.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is not explicitly stated, but the focus is on specific variants (e.g., M26I, C106A).",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "PARK7",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "106"
        },
        "variant_string_id": "PARK7 C106A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD)-associated genomic deletions and the destabilizing L166P point mutation lead to loss of the cytoprotective DJ-1 protein.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as loss of DJ-1 function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The C106A mutation abolishes ASK1 binding and cytoprotective activity.",
          "judgment": "Yes",
          "reasoning": "Protein interaction (ASK1) and functional assays (cytoprotection) are directly relevant.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Systematic testing of all cysteine and methionine mutants, including wild-type (wt) and [C106A]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Wild-type and known pathogenic variants were used as controls. Systematic testing implies replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants (e.g., L166P) and benign variants (peripheral cysteine mutants) were compared to [C106A]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Variant controls (pathogenic and benign) were explicitly used for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study systematically tested all cysteine and methionine mutants, with C106A abolishing ASK1 binding and cytoprotection.",
          "judgment": "No",
          "reasoning": "Statistical details (e.g., p-values) are not provided in the abstract.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested all cysteine and methionine mutants but does not specify the total number of control variants.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is not explicitly stated, but the focus is on specific variants.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "functional_evidence_strength": "PS3_moderate"
    },
    {
      "variant_id": {
        "Gene": "PARK7",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "46"
        },
        "variant_string_id": "PARK7 C46A"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD)-associated genomic deletions and the destabilizing L166P point mutation lead to loss of the cytoprotective DJ-1 protein.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as loss of DJ-1 function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Peripheral cysteine mutants (e.g., C46A) retain cytoprotective activity despite constitutive ASK1 binding.",
          "judgment": "Yes",
          "reasoning": "Protein interaction (ASK1) and functional assays (cytoprotection) are directly relevant.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Systematic testing of all cysteine and methionine mutants, including wild-type (wt) and [C46A]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Wild-type and known pathogenic variants were used as controls. Systematic testing implies replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants (e.g., L166P) and benign variants (peripheral cysteine mutants) were compared to [C46A]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Variant controls (pathogenic and benign) were explicitly used for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study systematically tested all cysteine and methionine mutants, with C46A retaining cytoprotective activity.",
          "judgment": "No",
          "reasoning": "Statistical details (e.g., p-values) are not provided in the abstract.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested all cysteine and methionine mutants but does not specify the total number of control variants.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is not explicitly stated, but the focus is on specific variants.",
          "next_step_or_outcome": "Max BS3_supporting"
        }
      ],
      "functional_evidence_strength": "BS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "PARK7",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "56"
        },
        "variant_string_id": "PARK7 C56A"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD)-associated genomic deletions and the destabilizing L166P point mutation lead to loss of the cytoprotective DJ-1 protein.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as loss of DJ-1 function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Peripheral cysteine mutants (e.g., C56A) retain cytoprotective activity despite constitutive ASK1 binding.",
          "judgment": "Yes",
          "reasoning": "Protein interaction (ASK1) and functional assays (cytoprotection) are directly relevant.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Systematic testing of all cysteine and methionine mutants, including wild-type (wt) and [C56A]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Wild-type and known pathogenic variants were used as controls. Systematic testing implies replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants (e.g., L166P) and benign variants (peripheral cysteine mutants) were compared to [C56A]DJ-1.",
          "judgment": "Yes",
          "reasoning": "Variant controls (pathogenic and benign) were explicitly used for comparison.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study systematically tested all cysteine and methionine mutants, with C56A retaining cytoprotective activity.",
          "judgment": "No",
          "reasoning": "Statistical details (e.g., p-values) are not provided in the abstract.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested all cysteine and methionine mutants but does not specify the total number of control variants.",
          "judgment": "10 or less",
          "reasoning": "The number of control variants is not explicitly stated, but the focus is on specific variants.",
          "next_step_or_outcome": "Max BS3_supporting"
        }
      ],
      "functional_evidence_strength": "BS3_supporting"
    }
  ]
}